Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





COVID-19 VaST Work Group Report – May 24, 2021										Related Pages
					The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical (VaST) Work Group has reviewed post-authorization COVID-19 vaccine safety data weekly since the start of the U.S. vaccination program in December 2020. Updates of VaST activities and VaST assessments of safety data were presented at ACIP meetings on January 27, March 1, April 14, April 23, and May 12, 2021; ACIP meetings are open to the public. In lieu of presentations at ACIP meetings, reports from VaST meetings on March 29 and May 17, 2021 have been posted on the ACIP website.
During the VaST session on May 24, 2021, members reviewed updated data on myocarditis and pericarditis after COVID-19 vaccination, including presentations from the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD), along with a brief update from the Department of Veteran Affairs (VA) about further plans for investigation.
Data from VAERS show that in the 30-day window following dose 2 mRNA COVID-19 vaccination, there was a higher number of observed than expected myocarditis/pericarditis cases in 16–24-year-olds.
Data from VSD do not show that rates of myocarditis/pericarditis reports in the window following COVID-19 vaccination differ from expected at this time; however, analyses suggest that these data need to be carefully followed as more persons in younger age groups are vaccinated. VSD found no concerns among the over 20 other adverse events of special interest being monitored.VaST members discussed the following key points:
Information should be provided to clinicians to enhance early recognition and appropriate management of persons who develop myocarditis or pericarditis following vaccination.
Further information on potential myocarditis or pericarditis cases should continue to be collected through medical record review of cases reported into VAERS and observed in VSD.
Data from vaccine safety monitoring systems for potential cases should continue to be obtained as vaccination rates increase in younger age groups.
Collaboration between cardiology, infectious diseases, and rheumatology specialists is needed to provide clinical guidance about early recognition, differential diagnosis, diagnostic testing, and appropriate management of persons who develop myocarditis or pericarditis.
Long-term follow up of patients with myocarditis or pericarditis is needed to understand clinical course and natural history following both COVID-19 infection and COVID-19 vaccination.Past reports from the VaST Work Group to ACIPVaST assessement of safety data
2022
February 4, 2022pdf icon
April 20, 2022pdf icon
May 19, 2022pdf icon2021
January 27, 2021pdf icon
March 1, 2021pdf icon
April 14, 2021pdf icon
April 23, 2021pdf icon
May 12, 2021pdf icon
June 23, 2021pdf icon
July 22, 2021pdf icon
August 30, 2021pdf icon
September 22, 2021pdf icon
October 21, 2021pdf icon
November 19, 2021pdf icon
December 16, 2021pdf icon
							
					
						Page last reviewed:  June 1, 2021					Content source: 	National Center for Immunization and Respiratory Diseases homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue